← Back to Search

Diagnostic Test

Quick Renal MRI for Pediatric Kidney Disease

N/A
Recruiting
Led By Ruthie Su, MD
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient is admitted to American Family Children's Hospital for a febrile UTI, suspected pyelonephritis, or diagnosed pyelonephritis undergoing clinical DMSA scan
History of more than one UTI in the past year
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial proposes a new, faster imaging technique for children with urinary tract problems that is injection-, sedation-, and radiation-free. It could potentially replace current scans and ease the burden of testing for kids with chronic renal disease.

Who is the study for?
This trial is for children and young adults (0-21 years) with kidney conditions like infections or scarring, who are already getting DMSA scans as part of their care. It's not for those uncomfortable with MRI, without signs of infection in urine tests, negative urine cultures, or who can't have an MRI due to other medical reasons.
What is being tested?
The study is testing a new 'quick renal MRI' method against the standard DMSA scan used to detect kidney infections and scarring. The goal is to see if this quick MRI can be a faster, safer option that doesn't need injections, sedation, or radiation.
What are the potential side effects?
Since the quick renal MRI does not use radiation, sedation, or injections unlike traditional imaging methods such as the DMSA scan; it's expected to have fewer risks. However specific side effects aren't listed since MRIs typically don’t involve any.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am in the hospital for a fever and kidney infection, getting a special kidney scan.
Select...
I have had more than one urinary tract infection in the last year.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Sensitivity of Quick MRI as Compared to DMSA scan in Diagnosis of Suspected Acute Pyelonephritis
Sensitivity of Quick MRI as compared to DMSA scan in Diagnosis of Renal Scars
Specificity of Quick MRI as compared to DMSA scan in Diagnosis of Renal Scars

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: DMSA/Quick MRIExperimental Treatment1 Intervention
All participants will go through DMSA and Quick MRI scan to help determine the validity of the Quick Renal MRI in pediatric kidney disease.

Find a Location

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor
1,237 Previous Clinical Trials
3,200,879 Total Patients Enrolled
1 Trials studying Urinary Tract Infection
65 Patients Enrolled for Urinary Tract Infection
Ruthie Su, MDPrincipal InvestigatorUniversity of Wisconsin, Madison
Shannon Cannon, MDPrincipal InvestigatorUniversity of Wisconsin, Madison

Media Library

Quick MRI (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT03959163 — N/A
Urinary Tract Infection Research Study Groups: DMSA/Quick MRI
Urinary Tract Infection Clinical Trial 2023: Quick MRI Highlights & Side Effects. Trial Name: NCT03959163 — N/A
Quick MRI (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03959163 — N/A
~0 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top